From Nasdaq: 2025-06-10 15:00:00

BrightSpring Health Services (BTSG) stock reached an all-time high of $25.57 on June 9, with a 120% surge over the past year, outperforming the Medical Services industry by defying sector trends and the S&P 500. Competitors like AMED and OPCH rose 2.7% and 12.2%, respectively.

The rise is attributed to BrightSpring’s market-beating first-quarter 2025 performance and improved Home Health star ratings, with over 80% of branches now rated 4 stars or higher. The company is confident in achieving full-year guidance for continued double-digit growth in revenues and EBITDA.

BrightSpring stock is undervalued compared to its industry, trading at a forward P/S ratio of 0.32, lower than peers like Amedisys and Option Care Health. With a Zacks Rank #2 (Buy), the company demonstrates strong operational momentum and remains undervalued, making it an attractive investment opportunity.

Investors are encouraged to buy BrightSpring stock now as the company shows strong operational momentum in its care segments and quality metrics improvements, leading to increased investor confidence. Trading at a lower forward P/S ratio compared to peers, BTSG remains undervalued. Explore Zacks’ Buys and Sells for only $1 to access all picks and portfolio services.



Read more at Nasdaq: BrightSpring Soars to All-Time High on Quality Strength: Still a Buy?